LISATA THERAPEUTICS, INC. — Director's Dealing 2016

Sep 30, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2016-09-29

Reporting Person: Preti Robert A (Director, See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-09-29	Stock Option	$4.77	A	20894	Acquired	2026-09-29	Common Stock (20894)	Direct

Footnotes

F1: These stock options were granted upon the Company's Compensation Committee approval on September 29, 2016, in consideration of the unpaid portion of the reporting person's discretionary 2015 target bonus.